Авторы

  • Amonov S.B.
  • Yusupaliyeva Sh.S.
  • Kasimova R.I.

Ключевые слова:

hepatitis B, hepatitis C, hepatitis D, epidemiology, treatment, genotypes, Central Asia, Uzbekistan.

Библиографические ссылки

Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund SH, Ali S. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review. Int J Infect Dis [Internet]. 2020 Mar 1 [cited 2025 Oct 29]; 104:510. Available from: https: //pmc.ncbi.nlm.nih.gov/articles/PMC11094609/

Gokcan H, Idilman R. Hepatitis D Infection in Asia: A Perspective From an Endemic Region. Clin Liver Dis (Hoboken) [Internet]. 2021 Jul 1 [cited 2025 Oct 29];18(1):26. Available from: https:// pmc.ncbi.nlm.nih.gov/articles/PMC8405052/

E. EH. Geographical features of viral hepatitis in the population of uzbekistan. “Экономика и социум” [Internet]. 2024 [cited 2025 Oct 29];(12-2 (127)). Available from: https://cyberleninka.ru/ article/n/geographical-features-of-viral-hepatitis-in-the-population-of-uzbekistan

Ismoilov UY, Musabaev EI, Khikmatullaeva AS, Ibadullaeva NS, Kan NG, Sadirova SS, et al. Hepatitis B and C landscape in Uzbekistan: epidemiological patterns revealed in a study of 1 040 000 people. The European Journal of Public Health [Internet]. 2025 Aug 21 [cited 2025 Oct 29];35(5):1014. Available from: https://pmc.ncbi.nlm.nih.gov/articles/ PMC12529272/

Mehmet D, Meliksah E, Serif Y, Gunay S, Tuncer Ö, Zeynep S. Prevalence of hepatitis B infection in the southeastern region of Turkey: Comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis [Internet]. 2005 [cited 2025 Oct 29]; 58(1):15–9. Available from: https:// www.researchgate.net/publication/8004669_Prevalence_of_hepattis_B_infection_in_the_southeasern_region_of_Turkey_Comparson_of_risk_fators_for_HBV_infection_in_rural_and_urban_areas

Yang S, Ding C, Cui Y, Wu J, Yu C, Chen P, et al. Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. BMJ Open [Internet]. 2017 Apr 1 [cited 2025 Oct 29];7(4): e014 947. Available from: https://bmjopen.bmj.com/con-tent/7/4/e014947

Khetsuriani N, Tursunova D, Kasimova R, Sharapov S, Stewart B, Matyakubov M, et al. Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination. Vaccine [Internet]. 2025 Feb 27 [cited 2025 Oct 29];48. Available from: https://pubmed.ncbi.nlm.nih.gov/3 9862544/

Sabeena S, Ravishankar N. Horizontal Modes of Transmission of Hepatitis B Virus (HBV): A Systematic Review and Meta-Analysis. Iran J Public Health [Internet]. 2022 [cited 2025 Oct 29]; 51(10): 2181. Available from: https://pmc.ncbi.nlm.nih.gov/ articles/PMC9647610/

Mansour-Ghanaei F, Joukar F, Yaseri M, Soati F, Atrkar-Roushan Z. Intrafamilial spread of hepatitis B virus in Guilan Province-North of Iran. Int J Mol Epidemiol Genet [Internet]. 2013 [cited 2025 Oct 29];4(4):250. Available from: https://pmc.ncbi.nlm. nih.gov/articles/PMC3852644/

di Filippo Villa D, Navas MC. Vertical Transmission of Hepatitis B Virus—An Update. Microorganisms [Internet]. 2023 May 1 [cited 2025 Oct 30];11(5):1140. Available from: https://pmc.ncbi. nlm.nih.gov/articles/PMC10221798/

Hepatitis: Preventing mother-to-child transmission of the hepatitis B virus [Internet]. [cited 2025 Oct 30]. Available from: https://www.who.int/ news-room/questions-and-answers/item/hepatitis-preventing-mother-to-child-transmission-of-the-hepatitis-b-virus

Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. Journal of Gastroenterology and Hepatology (Australia). 2011;26(SUPPL. 1):123–30.

Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health [Internet]. 2014 Jun 10 [cited 2025 Oct 30];6(1):605. Available from: https://pmc.ncbi. nlm.nih.gov/articles/PMC4062549/

Navabakhsh B, Mehrabi N, Estakhri A, Mohamadnejad M, Poustchi H. Hepatitis B Virus Infection during Pregnancy: Transmission and Prevention. Middle East J Dig Dis [Internet]. 2011 Sep [cited 2025 Oct 30];3(2):92. Available from: https://pmc. ncbi.nlm.nih.gov/articles/PMC4154922/

Deǧertekin H, Tuzcu A, Yalçin K. Horizontal transmission of HBV infection among students in Turkey. Public Health [Internet]. 2000 [cited 2025 Oct 30];114(5):411–2. Available from: https://pubmed.ncbi.nlm.nih.gov/11035467/

Doganci T, Uysal G, Kir T, Bakirtas A, Kuyucu N, Doganci L. Horizontal transmission of hepatitis B virus in children with chronic hepatitis B. World Journal of Gastroenterology: WJG [Internet]. 2005 Jan 21 [cited 2025 Oct 30];11(3):418. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC42 05352/

Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007 Jun;12(3):160–7.

Wong F, Pai R, Van Schalkwyk J, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Ann Hepatol [Internet]. 2014 Mar 1 [cited 2025 Oct 30];13(2):187–95. Available from: https://www. elsevier.es/es-revista-annals-hepatology-16-articu-lo-hepatitis-b-in-pregnancy-concise-S16652681193 08816

Huang L, Chen X, Wang Z. Total burden of hepatitis B and C attributed to injecting drug use in 204 countries and territories from 1990 to 2021: Analyses based on the Global Burden of Disease Study 2021. International Journal of Infectious Diseases [Internet]. 2025 Jan 1 [cited 2025 Oct 30]; 150:107293. Available from: https://www.scienced-irect.com/science/article/pii/S1201971224003643

Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund SH, Ali S. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review. Int J Infect Dis [Internet]. 2020 Mar 1 [cited 2025 Oct 30]; 104:510. Available from: https: //pmc.ncbi.nlm.nih.gov/articles/PMC11094609/

Rabaan AA, Bello KE, Radwan Z, Hassouneh AK, Alrasheed HA, Alotaibi J, et al. The Dual Burden of Hepatitis B and C Among Drug Users in Asia: The First Systematic Review and Meta-Analysis. Pathogens [Internet]. 2025 Apr 1 [cited 2025 Oct 30];14(4): 360. Available from: https://pmc.ncbi. nlm.nih.gov/articles/PMC12030361/

King KC, Strony R. Needlestick. 2023 May 1 [cited 2025 Oct 30]; Available from: https://www. ncbi.nlm.nih.gov/books/NBK493147/

Penalver J. Management of needlestick injuries in the health care setting. Virtual Mentor. 2005;7(10):683–6.

Bello KE, Mat Jusoh TNA, Irekeola AA, Abu N, Mohd Amin NAZ, Mustaffa N, et al. A Recent Prevalence of Hepatitis B Virus (HBV) Genotypes and Subtypes in Asia: A Systematic Review and Meta-Analysis. Healthcare (Switzerland) [Internet]. 2023 Apr 1 [cited 2025 Oct 30];11(7):1011. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10 094200/

Croagh CMN, Desmond P V., Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol [Internet]. 2015 [cited 2025 Oct 30];7(3): 289. Available from: https://pmc.ncbi.nlm.nih.gov/ articles/PMC4381158/

Avazova D, Kurbanov F, Tanaka Y, Sugiyama M, Radchenko I, Ruziev D, et al. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. J Med Virol. 2008 Feb 20;80(2):217–24.

N.S. D. Genotypes of hepatitis b virus in the samarkand region in patients with chronic viral hepatitis b+d. “Экономика и социум” [Internet]. 2025 [cited 2025 Oct 30] ;(6-1 (133)). Available from: https://cyberleninka.ru/article/n/genotypes-of-hepatitis-b-virus-in-the-samarkand-region-in-patients-with-chronic-viral-hepatitis-b-d

Останкова Ю.В., Семенов А.В., Буркитбаев Ж.К., Савчук Т.Н., Тотолян А.А. et al. Генетические варианты вируса гепатита b у первичных доноров в г. Астана, казахстан. Инфекция и иммунитет [Internet]. 2016 Dec 6 [cited 2025 Oct 30];6(4):359–65. Available from: https://iimmun.ru/iimm/article/view/448

Chan HLY, Wong ML, Hui AY, Hung LCT, Chan FKL, Sung JJY. Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients. J Clin Microbiol [Internet]. 2003 Mar 1 [cited 2025 Oct 30];41(3):1277. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC150268

Chan HLY, Hui AY, Wong ML, Tse AML, Hung LCT, Wong VWS, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut [Internet]. 2004 Oct [cited 2025 Oct 30];53(10):1494. Available from: https:// pmc.ncbi.nlm.nih.gov/articles/PMC1774221/

Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol [Internet]. 2011 [cited 2025 Oct 30];26(SUPPL. 1):123–30. Available from: /doi/pdf/ 10.1111/j.1440-1746.2010. 06541.x

Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: A longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at ba…. J Hepatol [Internet]. 2005 Sep 1 [cited 2025 Oct 30];43(3):411–7. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0168827805003089

Peng W, Gu H, Cheng D, Chen K, Wu C, Jiang C, et al. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Front Microbiol [Internet]. 2023 May 25 [cited 2025 Oct 30]; 14:1185492. Available from: https://ClinicalTrials.gov,

Cao L, Li L, Yang L, Zhou N, Zhang Y. Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis. Front Pharmacol [Internet]. 2025 Jan 20 [cited 2025 Oct 30]; 16:1507117. Available from: https://www.crd.york.ac.uk/prospero/,

Liu J, Bi Y, Ma X, Xin Y. Efficacy and Safety of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Treating Acute-on-Chronic Liver Failure with Hepatitis B Virus: A Network Meta-analysis. Infect Dis Ther [Internet]. 2025 Oct 1 [cited 2025 Oct 30];14(10). Available from: https://pubmed.ncbi.nlm.nih.gov/40903702/

Wang H, Wu L. A comparison of the therapeutic efficacy of Tenofovir Disoproxil Fumarate and Entecavir in patients with chronic Hepatitis-B. Pak J Med Sci [Internet]. 2024 Nov 1 [cited 2025 Oct 30];40(10):2390. Available from: https://pmc.ncbi. nlm.nih.gov/articles/PMC11568734/

Peng W, Gu H, Cheng D, Chen K, Wu C, Jiang C, et al. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Front Microbiol [Internet]. 2023 May 25 [cited 2025 Oct 30]; 14:1185492. Available from: https://ClinicalTrials.gov,

Liu J, Bi Y, Ma X, Xin Y. Efficacy and Safety of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Treating Acute-on-Chronic Liver Failure with Hepatitis B Virus: A Network Meta-analysis. Infect Dis Ther [Internet]. 2025 Oct 1 [cited 2025 Oct 30];14(10). Available from: https://pubmed.ncbi.nlm.nih.gov/40903702/

Xing T, Xu H, Cao L, Ye M. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLoS One [Internet]. 2017 Jan 1 [cited 2025 Oct 30];12(1). Available from: https://pubmed.ncbi. nlm.nih.gov/28107377/

Broquetas T, Carrión JA. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. Hepat Med [Internet]. 2022 Jul 29 [cited 2025 Oct 30]; 14:87–100. Available from: https://www.dovepress.com/current-perspectives-on-nucleostide-analogue-therapy-for-the-long-term-peer-reviewed-fulltext-article-HMER

Tajiri K, Hayashi Y, Murayama A, Muraishi N, Minemura M, Yasuda I. Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection. Viruses [Internet]. 2025 Jan 1 [cited 2025 Oct 30];17(1):44. Available from: https://pmc.ncbi.nlm. nih.gov/articles/PMC11769490/

Lee SK, Nam SW, Jang JW, Kwon JH. Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels. Diagnostics [Internet]. 2024 Mar 1 [cited 2025 Oct 30];14(5): 495. Available from: https:// pmc.ncbi.nlm.nih.gov/articles/PMC10931114/

Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) [Internet]. 2021 Mar 15 [cited 2025 Oct 30]; 8:637126. Available from: www.frontiersin.org

Uchida Y, Nakao M, Yamada S, Tsuji S, Uemura H, Kouyama JI, et al. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog. PLoS One [Internet]. 2022 Feb 1 [cited 2025 Oct 30];17(2): e0262764. Available from: https://journals.plos.org/plosone/ article?id=10.1371/journal.pone.0262764

Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy. Gastroenterology. 2024 Jan 1;166(1):168-177.e8.

Li F, Zhang Y, Liu C, Li J, Zhang D, Gao Y. Clinical outcomes of cessation of nucleoside/nucleotide analogues in Chinese patients with HBeAg-negative chronic hepatitis B. iLIVER [Internet]. 2024 Jun 1 [cited 2025 Oct 30];3(2):100093. Available from: https://www.sciencedirect.com/science/article/pii/S2772947824000185

Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol [Internet]. 2021 [cited 2025 Oct 30];13(9):1042. Available from: https://pmc. ncbi.nlm.nih.gov/articles/PMC8473499/

Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases [Internet]. 2021 [cited 2025 Oct 30];9(24):6979. Available from: https://pmc. ncbi.nlm.nih.gov/articles/PMC8409197/

Cathcart AL, Lik-Yuen Chan H, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis b infection. Antimicrob Agents Chemother [Internet]. 2018 Oct 1 [cited 2025 Oct 30];62(10). Available from: /doi/pdf/10.1128/aac.01064-18?download=true

Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut [Internet]. 2005 Jul [cited 2025 Oct 30];54(7):1009. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1774609/

Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol [Internet]. 2021 Sep 7 [cited 2025 Oct 30]; 12:733364. Available from: www.frontiersin.org

Suzuki F, Sezaki H, Hosaka T, Suzuki Y, Fujiyama S, Kawamura Y, et al. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol Res [Internet]. 2021 Apr 1 [cited 2025 Oct 30];51(4):503–8. Available from: https://pubmed.ncbi.nlm.nih.gov/33462964/

Chen R, Pei S, Chen Y, Tan L, Xue Y, Liu S, et al. Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. Front Med (Lausanne) [Internet]. 2021 Jul 8 [cited 2025 Oct 30]; 8:701061. Available from: www.frontiersin.org

Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. http:// www.xiahepublishing.com/ [Internet]. 2021 Oct 28 [cited 2025 Oct 30];9(5):769–91. Available from: https://www.xiahepublishing.com/m/23108819/JCTH-2021-00209

Shih YF, Liu CJ. Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses [Internet]. 2020 Jul 1 [cited 2025 Nov 3];12(7):741. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7412310/

Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol [Internet]. 2005 Apr 1 [cited 2025 Nov 3];4(2):100–6. Available from: https://www.elsevier.es/es-revista-annals-hepatology-16-articulo-hepatitis-b-virus-hepatitis-c-S1665268119320721

Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clinical Gastroenterology and Hepatology [Internet]. 2017 Jan 1 [cited 2025 Nov 3];15(1):132–6. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-risk-hepatitis-b-reactivating-some-patients-treated

Park YJ, Yi KY, Woo HY, Heo J, Song GA. Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study. PLoS One [Internet]. 2025 May 1 [cited 2025 Nov 3]; 20(5): e032 4019. Available from: https://pmc.ncbi.nlm.nih.gov/ articles/PMC12124557/

Maqsood Q, Sumrin A, Iqbal M, Younas S, Hussain N, Mahnoor M, et al. Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives. Antivir Ther [Internet]. 2023 Aug 1 [cited 2025 Nov 3];28(4). Available from: https://journals. sagepub.com/doi/10.1177/13596535231189643